{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T17:14:29Z","timestamp":1767892469329,"version":"3.49.0"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Associations between ganciclovir and severe nephrotoxicity are incompletely defined. Studies incorporating the time-varying nature of medication exposures and those that address confounding by indication are particularly scarce in children undergoing hematopoietic cell transplantation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>We identified children undergoing hematopoietic cell transplantation in the Pediatric Health Information System database and tracked them for 1 year following transplantation. The primary exposure of interest was the use of ganciclovir, which was treated as a time-varying variable. Secondary exposures of interest included cidofovir, foscarnet, amphotericin B, aminoglycosides, vancomycin and calcineurin inhibitors. The primary outcome of interest was renal replacement therapy, which was assessed using marginal structural Cox proportional hazards regression model incorporating time-varying variables and inverse-probability-of-treatment weight.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Of 17,924 children who underwent hematopoietic cell transplantation during the study period, 3078 (17.2%) had exposure to ganciclovir. In marginal structural Cox proportional hazards regression model incorporating time-varying variables and inverse-probability-of-treatment weight, ganciclovir was associated with an increased hazard of renal replacement therapy (adjusted hazard ratio: 1.84, 95% confidence interval: 1.22\u20132.76). Some of secondary exposures of interest, including cidofovir, amphotericin B and vancomycin, also were associated with renal replacement therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Intravenously administered ganciclovir is associated with renal dysfunction severe enough to require renal replacement therapy in pediatric hematopoietic cell transplant recipients. Ganciclovir should be used with caution and close monitoring. Approaches to mitigate the risks of nephrotoxicity should be investigated.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000004484","type":"journal-article","created":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T20:02:06Z","timestamp":1722369726000},"page":"1162-1167","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Nephrotoxicity of Intravenous Ganciclovir in Pediatric Hematopoietic Cell Transplant Recipients"],"prefix":"10.1097","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9906-6821","authenticated-orcid":false,"given":"Kengo","family":"Inagaki","sequence":"first","affiliation":[{"name":"From the Department of Pediatrics, University of Michigan"},{"name":"Institute for Healthcare Policy and Innovation, University of Michigan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark T.","family":"Vander Lugt","sequence":"additional","affiliation":[{"name":"From the Department of Pediatrics, University of Michigan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Riggsbee","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Michigan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason B.","family":"Weinberg","sequence":"additional","affiliation":[{"name":"From the Department of Pediatrics, University of Michigan"},{"name":"Department of Microbiology and Immunology, University of Michigan, Ann Arbor, Michigan."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,7,23]]},"reference":[{"key":"R1-20250614","doi-asserted-by":"crossref","first-page":"e260","DOI":"10.1016\/S1473-3099(19)30107-0","article-title":"Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7).","volume":"19","author":"Ljungman","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"R2-20250614","doi-asserted-by":"crossref","first-page":"173","DOI":"10.7326\/0003-4819-118-3-199302010-00003","article-title":"Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant.","volume":"118","author":"Goodrich","year":"1993","journal-title":"Ann Intern Med"},{"key":"R7-20250614","doi-asserted-by":"crossref","first-page":"257","DOI":"10.7326\/0003-4819-126-4-199702150-00001","article-title":"Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial.","volume":"126","author":"Lalezari","year":"1997","journal-title":"Ann Intern Med"},{"key":"R8-20250614","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJM199201233260401","article-title":"Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis.","volume":"326","year":"1992","journal-title":"N Engl J Med"},{"key":"R9-20250614","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1093\/jpids\/pit048","article-title":"Ganciclovir, foscarnet, and cidofovir: antiviral drugs not just for cytomegalovirus.","volume":"2","author":"Upadhyayula","year":"2013","journal-title":"J Pediatric Infect Dis Soc"},{"key":"R10-20250614","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1007\/s00467-007-0721-x","article-title":"Nephrotoxicity as a cause of acute kidney injury in children.","volume":"23","author":"Patzer","year":"2008","journal-title":"Pediatr Nephrol"},{"key":"R11-20250614","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM199204303261803","article-title":"A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation.","volume":"326","author":"Merigan","year":"1992","journal-title":"N Engl J Med"},{"key":"R12-20250614","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1001\/jama.2017.10569","article-title":"Effect of ganciclovir on IL-6 levels among cytomegalovirus-seropositive adults with critical illness: a randomized clinical trial.","volume":"318","author":"Limaye","year":"2017","journal-title":"JAMA"},{"key":"R13-20250614","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.3390\/jcm12051898","article-title":"Acute kidney injury in the ICU during ganciclovir treatment, an observational study.","volume":"12","author":"Al Fartousi","year":"2023","journal-title":"J Clin Med"},{"key":"R14-20250614","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1016\/j.bbmt.2020.03.019","article-title":"Impact of preemptive therapy for cytomegalovirus on toxicities after allogeneic hematopoietic cell transplantation in clinical practice: a retrospective single-center cohort study.","volume":"26","author":"Zavras","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"R15-20250614","first-page":"634","article-title":"Impact of antimicrobial drug-drug interactions on acute kidney injury after allogeneic hematopoietic cell transplantation.","volume":"29","author":"Wada","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"R16-20250614","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1111\/ajt.17171","article-title":"Antiviral toxicities in pediatric solid organ transplant recipients.","volume":"22","author":"Hayes","year":"2022","journal-title":"Am J Transplant"},{"key":"R17-20250614","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1093\/aje\/kwm324","article-title":"Immortal time bias in pharmaco-epidemiology.","volume":"167","author":"Suissa","year":"2008","journal-title":"Am J Epidemiol"},{"key":"R18-20250614","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/sim.4780020222","article-title":"The need for randomization in the study of intended effects.","volume":"2","author":"Miettinen","year":"1983","journal-title":"Stat Med"},{"key":"R19-20250614","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1080\/10428194.2022.2095628","article-title":"Pediatric cancer and hematopoietic stem cell transplantation patients requiring renal replacement therapy: results of the retrospective nationwide AIEOP study.","volume":"63","author":"Zama","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"R21-20250614","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/00001648-200009000-00011","article-title":"Marginal structural models and causal inference in epidemiology.","volume":"11","author":"Robins","year":"2000","journal-title":"Epidemiology"},{"key":"R22-20250614","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies.","volume":"34","author":"Austin","year":"2015","journal-title":"Stat Med"},{"key":"R23-20250614","doi-asserted-by":"crossref","first-page":"ii84","DOI":"10.1093\/ndt\/gfw341","article-title":"Marginal structural models in clinical research: when and how to use them?","volume":"32","author":"Williamson","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"R24-20250614","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1001\/jama.2020.9151","article-title":"Immortal time bias in observational studies.","volume":"325","author":"Yadav","year":"2021","journal-title":"JAMA"},{"key":"R25-20250614","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1086\/317451","article-title":"A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia.","volume":"31","author":"Wingard","year":"2000","journal-title":"Clin Infect Dis"},{"key":"R26-20250614","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1086\/491709","article-title":"Vancomycin: a history.","volume":"42","author":"Levine","year":"2006","journal-title":"Clin Infect Dis"},{"key":"R27-20250614","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1128\/AAC.23.1.138","article-title":"Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981.","volume":"23","author":"Farber","year":"1983","journal-title":"Antimicrob Agents Chemother"},{"key":"R28-20250614","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1001\/archinte.166.19.2138","article-title":"High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity.","volume":"166","author":"Hidayat","year":"2006","journal-title":"Arch Intern Med"},{"key":"R29-20250614","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","article-title":"Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists.","volume":"77","author":"Rybak","year":"2020","journal-title":"Am J Health Syst Pharm"},{"key":"R30-20250614","doi-asserted-by":"crossref","first-page":"e02042\u201317","DOI":"10.1128\/AAC.02042-17","article-title":"Prospective trial on the use of trough concentration versus area under the curve to determine therapeutic vancomycin dosing.","volume":"62","author":"Neely","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"R31-20250614","doi-asserted-by":"crossref","first-page":"e01293\u201317","DOI":"10.1128\/AAC.01293-17","article-title":"A quasi-experiment to study the impact of vancomycin area under the concentration-time curve-guided dosing on vancomycin-associated nephrotoxicity.","volume":"61","author":"Finch","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"R32-20250614","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/cid\/ciw709","article-title":"Risk of acute kidney injury in patients on concomitant vancomycin and piperacillin-tazobactam compared to those on vancomycin and cefepime.","volume":"64","author":"Navalkele","year":"2017","journal-title":"Clin Infect Dis"},{"key":"R33-20250614","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1093\/cid\/ciz1189","article-title":"Piperacillin-tazobactam added to vancomycin increases risk for acute kidney injury: fact or fiction?","volume":"71","author":"Avedissian","year":"2020","journal-title":"Clin Infect Dis"},{"key":"R34-20250614","doi-asserted-by":"crossref","first-page":"e173219","DOI":"10.1001\/jamapediatrics.2017.3219","article-title":"Association of acute kidney injury with concomitant vancomycin and piperacillin\/tazobactam treatment among hospitalized children.","volume":"171","author":"Downes","year":"2017","journal-title":"JAMA Pediatr"},{"key":"R35-20250614","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1001\/jama.2023.20583","article-title":"Cefepime vs piperacillin-tazobactam in adults hospitalized with acute infection: the ACORN randomized clinical trial.","volume":"330","author":"Qian","year":"2023","journal-title":"JAMA"},{"key":"R36-20250614","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1053\/j.ajkd.2005.02.010","article-title":"Antiviral drug-induced nephrotoxicity.","volume":"45","author":"Izzedine","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"R37-20250614","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1208\/s12248-021-00654-1","article-title":"PBPK simulation-based evaluation of ganciclovir crystalluria risk factors: effect of renal impairment, old age, and low fluid intake.","volume":"24","author":"Scotcher","year":"2021","journal-title":"AAPS J"},{"key":"R38-20250614","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/dkz325","article-title":"Mechanisms of antimicrobial-induced nephrotoxicity in children.","volume":"75","author":"Downes","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"R39-20250614","doi-asserted-by":"crossref","first-page":"F701","DOI":"10.1152\/ajprenal.00189.2017","article-title":"Distinct morphological features of acute tubular injury in renal allografts correlate with clinical outcome.","volume":"315","author":"Schumann-Bischoff","year":"2018","journal-title":"Am J Physiol Renal Physiol"},{"key":"R40-20250614","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1128\/AAC.40.8.1964","article-title":"Potent anti-murine cytomegalovirus activity and reduced nephrotoxicity of ganciclovir cyclic phosphonate.","volume":"40","author":"Smee","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"R41-20250614","doi-asserted-by":"crossref","first-page":"e01855","DOI":"10.1128\/AAC.01855-18","article-title":"Relationship of ganciclovir therapeutic drug monitoring with clinical efficacy and patient safety.","volume":"63","author":"Ritchie","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"R42-20250614","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/00042560-199803010-00007","article-title":"Pharmacokinetics of oral ganciclovir alone and in combination with zidovudine, didanosine, and probenecid in HIV-infected subjects.","volume":"17","author":"Cimoch","year":"1998","journal-title":"J Acquir Immune Defic Syndr Hum Retrovirol"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000004484","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T23:05:14Z","timestamp":1749942314000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000004484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,23]]},"references-count":37,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000004484","relation":{},"ISSN":["0891-3668","1532-0987"],"issn-type":[{"value":"0891-3668","type":"print"},{"value":"1532-0987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,23]]}}}